Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Crestor Should Be Withdrawn For Safety Reasons, Public Citizen Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Petition cites 22 cases of "serious" post-marketing events, including rhabdomyolysis, kidney problems and bleeding, in the U.S., U.K. and Canada.

You may also be interested in...



Crestor May Be Safer Than Other Statins, FDA Tells Public Citizen

There is no evidence to suggest Crestor (rosuvastatin) should be withdrawn because of its renal or muscle toxicity profiles, FDA says in its rejection of Public Citizen's petition. "For any degree of LDL-lowering, rosuvastatin is as safe, and may well be safer than, any other marketed statin with regard to muscle toxicity," FDA says.

Crestor May Be Safer Than Other Statins, FDA Tells Public Citizen

There is no evidence to suggest Crestor (rosuvastatin) should be withdrawn because of its renal or muscle toxicity profiles, FDA says in its rejection of Public Citizen's petition. "For any degree of LDL-lowering, rosuvastatin is as safe, and may well be safer than, any other marketed statin with regard to muscle toxicity," FDA says.

Celebrex, Bextra To Be Targets Of Public Citizen Withdrawal Petition

The watchdog group plans to file a petition in the next week calling for the withdrawal of Pfizer's COX-2 inhibitors. Celebrex and Bextra are among 180 currently marketed drugs Public Citizen advises consumers "do not use" on its expanded worstpills.org website.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel